SantinCAS# 27782-63-4 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 27782-63-4 | SDF | Download SDF |
PubChem ID | 5281695 | Appearance | Yellow powder |
Formula | C18H16O7 | M.Wt | 344.3 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Synonyms | Centauridin; 5,7-Dihydroxy 3,4',6-trimethoxyflavone; 6-Hydroxykaempferol 3,4',6-trimethyl ether; 3-Methylbetuletol | ||
Solubility | Soluble in methan | ||
Chemical Name | 5,7-dihydroxy-3,6-dimethoxy-2-(4-methoxyphenyl)chromen-4-one | ||
SMILES | COC1=CC=C(C=C1)C2=C(C(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC | ||
Standard InChIKey | DWZAJFZEYZIHPO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H16O7/c1-22-10-6-4-9(5-7-10)16-18(24-3)15(21)13-12(25-16)8-11(19)17(23-2)14(13)20/h4-8,19-20H,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Santin Dilution Calculator
Santin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9044 mL | 14.5222 mL | 29.0444 mL | 58.0889 mL | 72.6111 mL |
5 mM | 0.5809 mL | 2.9044 mL | 5.8089 mL | 11.6178 mL | 14.5222 mL |
10 mM | 0.2904 mL | 1.4522 mL | 2.9044 mL | 5.8089 mL | 7.2611 mL |
50 mM | 0.0581 mL | 0.2904 mL | 0.5809 mL | 1.1618 mL | 1.4522 mL |
100 mM | 0.029 mL | 0.1452 mL | 0.2904 mL | 0.5809 mL | 0.7261 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5,5'-Dihydroxy-3,8,3',4'-tetramethoxy-6,7-methylenedioxyflavone
Catalog No.:BCN9544
CAS No.:82668-96-0
- 4"-O-Acetylastilbin
Catalog No.:BCN9543
CAS No.:1298135-49-5
- (1R,6R,9R)-6,9,11-Trihydroxy-4,7-megastigmadien-3-one 11-O-glucoside
Catalog No.:BCN9542
CAS No.:289914-68-7
- Atalafoline
Catalog No.:BCN9541
CAS No.:107259-49-4
- Atalaphylline
Catalog No.:BCN9540
CAS No.:28233-35-4
- 8,8''-Biskoenigine
Catalog No.:BCN9539
CAS No.:477890-82-7
- Buxifoliadine C
Catalog No.:BCN9538
CAS No.:263007-67-6
- 5-Hydroxy-3,6,7,8,3'-pentamethoxy-4',5'-methylenedioxyflavone
Catalog No.:BCN9537
CAS No.:82669-01-0
- 1-Prenyl-2-methoxy-6-formyl-8-hydroxy-9H-carbazole
Catalog No.:BCN9536
CAS No.:484678-79-7
- Quercetin 3,7-di-O-rhamnoside
Catalog No.:BCN9535
CAS No.:28638-13-3
- Murrayamine C
Catalog No.:BCN9534
CAS No.:73385-58-7
- Murrastinine C
Catalog No.:BCN9533
CAS No.:20105-20-8
- 6-Methoxykaempferol 3-O-galactoside
Catalog No.:BCN9546
CAS No.:72945-43-8
- Coryximine
Catalog No.:BCN9547
CAS No.:127460-61-1
- Buxifoliadine H
Catalog No.:BCN9548
CAS No.:263007-72-3
- 7-(3'-Carboxybutoxy)coumarin
Catalog No.:BCN9549
CAS No.:16851-01-7
- cis-Abienol
Catalog No.:BCN9550
CAS No.:17990-16-8
- Aesculioside D
Catalog No.:BCN9551
CAS No.:254896-66-7
- Ampelopsin A
Catalog No.:BCN9552
CAS No.:130608-11-6
- Kaempferol 3,5-dimethyl ether
Catalog No.:BCN9553
CAS No.:1486-65-3
- Acersaponin I
Catalog No.:BCN9554
CAS No.:1257940-29-6
- 2,3-Dihydro-6-methylginkgetin
Catalog No.:BCN9555
CAS No.:1013649-09-6
- 3-Formylcarbazole
Catalog No.:BCN9556
CAS No.:51761-07-0
- Vitisin A
Catalog No.:BCN9557
CAS No.:142449-89-6
Description of Cryptosporidium ornithophilus n. sp. (Apicomplexa: Cryptosporidiidae) in farmed ostriches.[Pubmed:32641157]
Parasit Vectors. 2020 Jul 8;13(1):340.
BACKGROUND: Avian cryptosporidiosis is a common parasitic disease that is caused by five species, which are well characterised at the molecular and biological level, and more than 18 genotypes for which we have limited information. In this study, we determined the occurrence and molecular characteristics of Cryptosporidium spp. in farmed ostriches in the Czech Republic. METHODS: The occurrence and genetic identity of Cryptosporidium spp. were analysed by microscopy and PCR/sequencing of the small subunit rRNA, actin, HSP70 and gp60 genes. Cryptosporidium avian genotype II was examined from naturally and experimentally infected hosts and measured using differential interference contrast. The localisation of the life-cycle stages was studied by electron microscopy and histologically. Infectivity of Cryptosporidium avian genotype II for cockatiels (Nymphicus hollandicus (Kerr)), chickens (Gallus gallus f. domestica (L.)), geese (Anser anser f. domestica (L.)), SCID and BALB/c mice (Mus musculus L.) was verified. RESULTS: A total of 204 individual faecal samples were examined for Cryptosporidium spp. using differential staining and PCR/sequencing. Phylogenetic analysis of small subunit rRNA, actin, HSP70 and gp60 gene sequences showed the presence of Cryptosporidium avian genotype II (n = 7) and C. ubiquitum Fayer, Santin & Macarisin, 2010 IXa (n = 5). Only ostriches infected with Cryptosporidium avian genotype II shed oocysts that were detectable by microscopy. Oocysts were purified from a pooled sample of four birds, characterised morphometrically and used in experimental infections to determine biological characteristics. Oocysts of Cryptosporidium avian genotype II measure on average 6.13 x 5.15 mum, and are indistinguishable by size from C. baileyi Current, Upton & Haynes, 1986 and C. avium Holubova, Sak, Horcickova, Hlaskova, Kvetonova, Menchaca, McEvoy & Kvac, 2016. Cryptosporidium avian genotype II was experimentally infectious for geese, chickens and cockatiels, with a prepatent period of four, seven and eight days post-infection, respectively. The infection intensity ranged from 1000 to 16,000 oocysts per gram. None of the naturally or experimentally infected birds developed clinical signs in the present study. CONCLUSIONS: The molecular and biological characteristics of Cryptosporidium avian genotype II, described here, support the establishment of a new species, Cryptosporidium ornithophilus n. sp.